Kura Oncology, Inc. (NASDAQ:KURA – Free Report) – Research analysts at Cantor Fitzgerald issued their FY2025 earnings per share estimates for Kura Oncology in a research report issued to clients and investors on Tuesday, January 21st. Cantor Fitzgerald analyst L. Watsek expects that the company will earn ($2.94) per share for the year. Cantor Fitzgerald currently has a “Overweight” rating on the stock. The consensus estimate for Kura Oncology’s current full-year earnings is ($2.44) per share.
Kura Oncology (NASDAQ:KURA – Get Free Report) last posted its quarterly earnings results on Thursday, November 7th. The company reported ($0.63) EPS for the quarter, topping analysts’ consensus estimates of ($0.64) by $0.01. During the same quarter in the prior year, the firm posted ($0.50) earnings per share.
Get Our Latest Analysis on Kura Oncology
Kura Oncology Stock Performance
Shares of KURA opened at $8.21 on Wednesday. Kura Oncology has a 12-month low of $6.98 and a 12-month high of $24.17. The company has a current ratio of 11.47, a quick ratio of 11.47 and a debt-to-equity ratio of 0.02. The company has a market cap of $638.41 million, a PE ratio of -3.48 and a beta of 0.81. The stock has a 50-day moving average price of $9.88 and a 200-day moving average price of $16.09.
Institutional Trading of Kura Oncology
A number of large investors have recently made changes to their positions in KURA. nVerses Capital LLC bought a new stake in shares of Kura Oncology in the third quarter worth about $25,000. Point72 DIFC Ltd purchased a new position in Kura Oncology in the 3rd quarter worth about $146,000. Quarry LP bought a new stake in Kura Oncology during the 2nd quarter valued at about $196,000. Erste Asset Management GmbH purchased a new stake in Kura Oncology in the 3rd quarter valued at about $215,000. Finally, Bellevue Group AG grew its stake in Kura Oncology by 36.0% in the 3rd quarter. Bellevue Group AG now owns 13,600 shares of the company’s stock worth $266,000 after acquiring an additional 3,600 shares in the last quarter.
About Kura Oncology
Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.
Further Reading
- Five stocks we like better than Kura Oncology
- What is the FTSE 100 index?
- Market Momentum: 3 Stocks Poised for Significant Breakouts
- Learn Technical Analysis Skills to Master the Stock Market
- Kinder Morgan’s Uptrend is Only Half Over: New Highs Are Coming
- Health Care Stocks Explained: Why You Might Want to Invest
- Momentum Builders: 3 Stocks Positioned to Shine This Quarter
Receive News & Ratings for Kura Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology and related companies with MarketBeat.com's FREE daily email newsletter.